EUVIMEDEUVIMED entdecken
Crossref

Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances

Jinhui Zhang, Susan Daniela Selaya, Diaa Shakleya, Adil Mohammad, Patrick J Faustino

Journal of Pharmaceutical Sciences · 2023-05 · 112 (5) · 1246-1254

DOI: 10.1016/j.xphs.2022.12.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023-05. Verfasst von Jinhui Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food…. Hauptthemen laut MEDLINE: Losartan, Nitrosamines. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Starting in July 2018, the FDA alerted patients and health care professionals to the recall of ARBs such as valsartan by several pharmaceutical companies because of their potential contamination with carcinogenic nitrosamine impurities, including: (1) N-nitrosodimethylamine (NDMA), (2) N-nitrosodiethylamine (NDEA), (3) N-nitrosoethylisopropylamine (NEIPA), (4) N-nitrosodiisopropylamine (NDIPA), (5) N-nitrosodibutylamine (NDBA) and (6) N-nitroso-N-methyl-4-aminobutyric acid (NMBA). The FDA initiated a laboratory investigation to develop analytical procedures to test multiple lots of marketed ARB drugs to determine the possible presence of carcinogenic impurities and, if present, quantitate the levels of these impurities. Here the FDA laboratory developed and validated an automated micro-solid phase extraction MS/MS method, where all the analytes are not separated prior to elution to the MS, to simultaneously quantify NEIPA, NDIPA, NDBA and NMBA in ARB drug substances with an instrument sample analysis time of 12 seconds. The method was validated according to the ICH Q2(R1) guideline, and was determined to be specific, accurate, precise and linear over the corresponding nitrosamine analytical ranges. The method has been successfully implemented to quantitate the four nitrosamine impurities in 129 generic losartan, valsartan, olmesartan, irbesartan and telmisartan drug substance samples from 32 lots; and 32 losartan and valsartan drug product samples from 6 lots.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LosartanNitrosaminesHumansAngiotensin Receptor AntagonistsTandem Mass SpectrometryAngiotensin-Converting Enzyme InhibitorsValsartan

Stichwörter der Autor:innen

Advanced analyticsAngiotensin II receptor blockersLosartanNitrosamineRapidFire-MS/MSValsartan

Substanzen

LosartanAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsdibutylnitrosamineNitrosaminesValsartan

Autor:innen und Institutionen

  • Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Life Science Build…

Zitieren

APA

Zhang, J., Selaya, S. D., Shakleya, D., Mohammad, A., & Faustino, P. J. (2023). Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances. Journal of Pharmaceutical Sciences, 112(5), 1246-1254. https://doi.org/10.1016/j.xphs.2022.12.005

Vancouver

Zhang J, Selaya SD, Shakleya D, Mohammad A, Faustino PJ. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances. Journal of Pharmaceutical Sciences. 2023;112(5):1246-1254. doi:10.1016/j.xphs.2022.12.005

BibTeX
@article{Zhang2023,
  author = {Zhang, Jinhui and Selaya, Susan Daniela and Shakleya, Diaa and Mohammad, Adil and Faustino, Patrick J},
  title = {Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2023},
  volume = {112},
  number = {5},
  pages = {1246--1254},
  doi = {10.1016/j.xphs.2022.12.005}
}
Kostenlos starten →